Clovis Oncology (CLVS) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall St set for lower open as Alphabet results reignite AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
Clovis Oncology (CLVS) PT Slashed 74% to $19 at RBC Capital
October 31, 2018 7:14 AM EDTRBC Capital analyst Kennen MacKay lowered the price target on Clovis Oncology (NASDAQ: CLVS) to $19.00 (from $73.00) while maintaining a Outperform rating.
MacKay notes Rubraca's PARPi competition impact sets in.
... More


